References
- Fishbein L, Nathanson KL. Pheochromocytoma and Paraganglioma: Understanding the Complexities of the Genetic Background. Cancer Genet 2012;205:1–11.
- Luca F, Holl N, Vinzio S et al. Manifestations cardiaques des phéochromocytomes. Ann Endocrinol 2009:70:43–47.
- Galetta F, Franzoni F, Bernini G et al. Cardiovascular complications in patients with pheochromocytoma: A mini-review. Biomed Pharmacother 2010;64:505–509.
- Lenders JW, Kerstens MN, Laurence AMAR et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 2020;38: 1443–1456.
- Prejbisz A, Lenders JW, Eisenhofer G et al. Mortality Associated with Phaeochromocytoma. Horm Metab Res 2013, 45;2:154–158.
- Berends AMA, Eisenhofer G, Fishbein L et al. Intricacies of the molecular machinery of catecholamine biosynthesis and secretion by chromaffin cells of the normal adrenal medulla and in pheochromocytoma and paraganglioma. Cancers 2019;11(8):1121.
- Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocr Regul 2019;53:191–212.
- Mañas-Martínez AB, Medrano-Navarro AL, Aguillo-Gutiérrez E. Hemorrhagic pheochromocytoma presenting as severe hypertension with myocardial infarction. Ann Endocrinol 2017;78:54–6.
- Manger WM. The protean manifestations of pheochromocytoma. Horm Metab Res 2009; 41:658–63.
- Reisch N, Peczkowska M, Januszewicz A et al. Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens 2006;24:2331–9.
- Galetta F, Franzoni F, Bernini G et al. Cardiovascular complications in patients with pheochromocytoma: a mini-review. Biomed Pharmacother 2010;64:505–9.
- Fleg JL, Evans GW, Margolis KL et al. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial. Hypertension 2016;68:888–895.
- Gu YW, Poste J, Kunal M et al. Cardiovascular manifestations of pheochromocytoma. Cardiol Rev 2017;25:215–22.
- Nazari MA, Rosenblum JS, Haigney MC et al. Pathophysiology and acute management of tachyarrhythmias in pheochromocytoma: JACC review topic of the week. J Am Coll Cardiol 2020;76:451–64.
- Gupta MK, Neelakantan TV, Sanghamitra M et al. An assessment of the role of reactive oxygen species and redox signaling in norepinephrine-induced apoptosis and hypertrophy of H9c2 cardiac myoblasts. Antioxid Redox Signal 2006;8:1081–93.
- Y-Hassan S, Falhammar H. Cardiovascular manifestations and complications of pheochromocy-tomas and paragangliomas. J Clin Med 2020;9:2435.
- Press D, Akyuz M, Dural C et al. Predictors of recurrence in pheochromocytoma. J Am Coll Surg 2014;156:1523–1528.
- Amar L, Servais A, Gimenez-Roqueplo AP et al.Year of diagnosis, features at presentation and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005;90:2110–2116.
- Hamidi O, Young WF, Iñiguez-Ariza NM et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 2017;102:3296–3305.
- Lenders JWM, Duh QY, Eisenhofer G et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915–1942.